Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients

M. D. Stegall, T. Diwan, S. Raghavaiah, L. D. Cornell, J. Burns, P. G. Dean, F. G. Cosio, M. J. Gandhi, W. Kremers, J. M. Gloor

Research output: Contribution to journalArticlepeer-review

393 Scopus citations


Sensitized renal transplant recipients with high levels of donor-specific alloantibody (DSA) commonly develop antibody-mediated rejection (AMR), which may cause acute graft loss or shorten allograft survival. We examined the efficacy of terminal complement inhibition with the humanized anti-C5 antibody, eculizumab, in the prevention AMR in renal transplant recipients with a positive crossmatch against their living donor. The incidence of biopsy-proven AMR in the first 3 months posttransplant in 26 highly sensitized recipients of living donor renal transplants who received eculizumab posttransplant was compared to a historical control group of 51 sensitized patients treated with a similar plasma exchange (PE)-based protocol without eculizumab. The incidence of AMR was 7.7% (2/26) in the eculizumab group compared to 41.2% (21/51) in the control group (p = 0.0031). Eculizumab also decreased AMR in patients who developed high levels of DSA early after transplantation that caused proximal complement activation. With eculizumab, AMR episodeswere easily treated with PE reducing the need for splenectomy. On 1-year protocol biopsy, transplant glomerulopathywas found to be present in 6.7% (1/15) eculizumab-treated recipients and in 35.7% (15/42) of control patients (p = 0.044). Inhibition of terminal complement activation with eculizumab decreases the incidence of early AMR in sensitized renal transplant recipients (ClincalTrials.gov number NCT006707).

Original languageEnglish (US)
Pages (from-to)2405-2413
Number of pages9
JournalAmerican Journal of Transplantation
Issue number11
StatePublished - Nov 2011


  • Alloantibodies
  • Anti-HLA antibodies
  • Antibody-mediated rejection
  • Chronic rejection
  • Complement
  • Kidney transplantation
  • Sensitized recipients

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)


Dive into the research topics of 'Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients'. Together they form a unique fingerprint.

Cite this